 | Up a level |
Klyuchnikov, Evgeny; Badbaran, Anita; Massoud, Radwan; Freiberger, Petra; Wolschke, Christine; Ayuk, Francis; Fehse, Boris; Bacher, Ulrike; Kröger, Nicolaus (2024). Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR. Leukemia, 38(2), pp. 386-388. Nature Publishing Group 10.1038/s41375-024-02148-3
Klyuchnikov, Evgeny; Langebrake, Claudia; Badbaran, Anita; Dadkhah, Adrin; Massoud, Radwan; Freiberger, Petra; Ayuk, Francis; Janson, Dietlinde; Wolschke, Christine; Bacher, Ulrike; Kröger, Nicolaus (2023). Individualized busulfan dosing improves outcomes compared to fixed dose administration in pre-transplant MRD positive AML patients with intermediate risk undergoing allogeneic stem cell transplantation in CR. European journal of haematology, 110(2), pp. 188-197. Wiley 10.1111/ejh.13893
Klyuchnikov, Evgeny; Badbaran, Anita; Massoud, Radwan; Fritsche-Friedland, Ulrike; Freiberger, Petra; Ayuk, Francis; Wolschke, Christine; Bacher, Ulrike; Kröger, Nicolaus (2022). Post-transplant day +100 MRD detection rather than mixed chimerism predicts relapses after allo-SCT for intermediate risk AML patients transplanted in CR. Transplantation and cellular therapy, 28(7), 374.e1-374.e9. Elsevier 10.1016/j.jtct.2022.04.009
Klyuchnikov, Evgeny; Badbaran, Anita; Massoud, Radwan; Fritsche-Friedland, Ulrike; Janson, Dietlinde; Ayuk, Francis; Christopeit, Maximilian; Wolschke, Christine; Bacher, Ulrike; Kröger, Nicolaus (2022). Post-Transplantation Multicolored Flow Cytometry–Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia. Transplantation and cellular therapy, 28(5), 267.e1-267.e7. Elsevier 10.1016/j.jtct.2022.01.014
Klyuchnikov, Evgeny; Badbaran, Anita; Massoud, Radwan; Fritsche-Friedland, Ulrike; Janson, Dietlinde; Ayuk, Francis; Wolschke, Christine; Bacher, Vera; Kröger, Nicolaus (2021). Enhanced immune reconstitution of γδ T cells after allograft overcomes negative impact of pre-transplant MRD positive status in AML patients.: γδ T cells and MRD+ AML. Transplantation and cellular therapy, 27(10), pp. 841-850. Elsevier 10.1016/j.jtct.2021.06.003
